Nomogram for predicting overall survival (OS) in patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) or Gem alone for metastatic pancreatic cancer (MPC).

David  Goldstein

Stock and Other Ownership Interests  - Sirtex Medical

Research Funding - Amgen (Inst); Bayer (Inst); celgene (Inst); pfizer (Inst)

Daniel D.  Von Hoff

Employment - McKesson

Stock and Other Ownership Interests  - Anthem Inc; Capella Therapeutics; Cell Therapeutics; CerRx; McKesson; Medtronic; Stromatis Pharma; SynDevRx; Systems Oncology; UnitedHealthcare

Honoraria - Celgene

Consulting or Advisory Role - 7 Hills Pharma; AADi; Actinium Pharmaceuticals; Aduro Biotech; Aeglea Biotherapeutics; Alethia Biotherapeutics; Alpha Cancer Technologies; Aptose Biosciences; ARIAD; ARMO BioSciences; Arvinas; Athenex; Bellicum Pharmaceuticals; BeyondSpring Pharmaceuticals; Bicycle Therapeutics; BiolineRx; Biological Dynamics; Bionomics; Boston Biomedical; Bristol-Myers Squibb; CanBas; Cancer Prevention Pharmaceuticals; Cerulean Pharma; CORRONA; CV6 Therapeutics ; CytomX Therapeutics; Daiichi Sankyo; Deciphera; Defined Health; DNAtrix; EMD Serono; Esperance Pharmaceuticals; Evelo Therapeutics; Fate Therapeutics; FibroGen; Five Prime Therapeutics; FORMA Therapeutics; Formula Pharmaceuticals; Fujifilm; Geistlich Pharma; Genzada Pharmaceuticals; Gilead Sciences; HealthCare Pharmaceuticals; Histogen; Horizon Discovery; Horizon Pharma; HUYA Bioscience International; Idera; Ignyta; Imaging Endpoints; Immodulon Therapeutics; Immunophotonics; Innate Pharma; Insys Therapeutics; Intezyne Technologies; Janssen Diagnostics; Jounce Therapeutics; Kalos Therapeutics; Kinex; Kura Oncology; L.E.A.F. Pharmaceuticals; Lantern Pharma; Lilly; Lixte Biotechnology; MBC Pharma; Medical Prognosis Institute; miRNA Therapeutics; Novocure; Oncology Venture; Oncolytics; Oncolyze; Pain Therapeutics; Pfizer; Pharmamab; Phosplatin Therapeutics; Progen; Reflexion Medical; RenovoRx; Samus Therapeutics; Senhwa Biosciences; SOTIO; Strategia Therapeutics; Sumitomo Dainippon; Sun Biopharma; Superlab Far East; Synergene; Systems Imagination; Tavistock Life Sciences; TD2; Tolero Pharmaceuticals; TP Therapeutics; Trovagene; Ventana Medical Systems; Verily; Vertex; Viamet Pharmaceuticals

Research Funding - 3-V Biosciences (Inst); Abbvie (Inst); Aduro Biotech (Inst); Agios (Inst); ArQule (Inst); Baxalta (Inst); Celgene (Inst); Cleave Biosciences (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Endocyte (Inst); ESSA (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Minneamrita Therapeutics (Inst); miRNA Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Proderm IQ (Inst); Samumed (Inst); Strategia (Inst); Trovagene (Inst); Verastem (Inst)

Patents, Royalties, Other Intellectual Property - 2-aryl-pyridylazoles for the Treatment of Solid Tumors such as Pancreatic Cancer (pending); Intramedullary Catheter; Methods and Kits to Predict Therapeutic Outcome of BTK Inhibitors (pending); Methods of Human Prostate Cancer; Methods, Compounds and Compositions with Genotype Selective Anticancer Activity (pending); Muscle Fatigue Substance Cytokines and Methods of Inhibiting Tumor Growth Therewith (pending); Protein Kinase Inhibitors (pending); Targeting a Protein PRC1 for the Treatment of Pancreatic Cancer (pending); Targeting a Protein Tyrosine Phosphotase-PRL-1 for the Treatment of Pancreatic Cancer (pending); Targeting Ecto-5-Nucleotidase (Cd73) for the Treatment of Pancreatic Cancer; Targeting Ecto-5-Nucleotidase (CD73) for the Treatment of Pancreatic Cancer (pending); Targeting Site-2 Protease (S2P) for the Treatment of Pancreatic Cancer (pending); Use of 5,6-Dihydro-5-Azacytidine in the Treatment of Prostate Cancer

E. Gabriela  Chiorean

Consulting or Advisory Role - Genentech/Roche; Merrimack; Novocure; Pfizer; Pfizer

Research Funding - Bristol-Myers Squibb; Celgene; Genentech; Ignyta; Incyte; Newlink Genetics; PRISM Pharma; Spectrum Pharmaceuticals; Stemline Therapeutics

Travel, Accommodations, Expenses - Celgene

Michele  Reni

No Relationships to Disclose

Josep  Tabernero

Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Celgene; Chugai Pharma; Lilly; Merck Serono; MSD; Novartis; Pfizer; Roche; Sanofi; Symphony Evolution; Taiho Pharmaceutical; Takeda

Ramesh K.  Ramanathan

Honoraria - Cerulean Pharma; Insys Therapeutics; Novocure; Pharmacyclics; Taiho Pharmaceutical

Consulting or Advisory Role - Cerulean Pharma; Insys Therapeutics; Novocure; Pharmacyclics

Research Funding - Abbvie (Inst); Bayer (Inst); Berg Pharma (Inst); Biomarin (Inst); Boston Biomedical (Inst); Celgene (Inst); Halozyme (Inst); Merck/Schering Plough (Inst); Merrimack (Inst); Superlab Far East (Inst); Tekmira (Inst); Verastem (Inst)

Abdalla  Aly

Employment - Pharmerit

Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Celldex

Research Funding - Bristol-Myers Squibb; Celgene; Celldex

Marc  Botteman

Employment - Pharmerit

Leadership - Pharmerit

Stock and Other Ownership Interests  - Pharmerit

Consulting or Advisory Role - Bristol-Myers Squibb; Celgene

Research Funding - Bristol-Myers Squibb; Celgene

Julia  Wilkersen

Employment - Pharmerit

Sandra  Margunato-Debay

Employment - Bristol-Myers Squibb (I); Celgene

Brian  Lu

No Relationships to Disclose

Chrystal Ursula  Louis

Employment - Celgene

Markus Frederic  Renschler

Employment - Celgene

Leadership - Celgene

Stock and Other Ownership Interests  - Celgene

Patents, Royalties, Other Intellectual Property - Celgene

Travel, Accommodations, Expenses - Celgene

Desmond Micahel Thomas  McGovern

Employment - Celgene

Stock and Other Ownership Interests  - Celgene

Chee Khoon  Lee

Honoraria - AstraZeneca

Travel, Accommodations, Expenses - AstraZeneca